GSK3B
Glycogen synthase kinase-3 beta
As of the edition of 20 October 2026, GSK3B (glycogen synthase kinase-3 beta, UniProt P49841) has 5 drugs tested at it and 13 companies on the list, 1 on route A and 1 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P49841
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- In more than one place
- Solved structures
- 123
- Disease areas
- Nervous system; Mental health; Cancer; Inherited and neonatal; Injuries; Blood and lymph; Bones, joints and muscles; Nutrition and metabolism
- Registered trials of its drugs
- 87
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 2 |
| Active | 2 |
| Stopped | 1 |
| Total | 5 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Lithium carbonate | Marketed | Phase 4 | none listed |
| Elraglusib | Active | Phase 2 | none listed |
| Tideglusib | Active | Phase 3 | none listed |
| LY-2090314 | Stopped | Phase 2 | none listed |
| Lithium citrate anhydrous | Marketed | No phase stated | none listed |
5 of 5 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 1 |
| Route B | 1 |
| Engaged | 11 |
| Total on the list | 13 |
The other 11 companies at GSK3B
In the product13 companies in all; 11 are not named here, and no score is.
See the 13 companies at GSK3B, ranked, with the facts behind eachRequest access. Nothing is shown until you do.